Alexander M Lesokhin

Alexander M Lesokhin

UNVERIFIED PROFILE

Are you Alexander M Lesokhin?   Register this Author

Register author
Alexander M Lesokhin

Alexander M Lesokhin

Publications by authors named "Alexander M Lesokhin"

Are you Alexander M Lesokhin?   Register this Author

38Publications

1607Reads

41Profile Views

Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma.

Cancer Immunol Res 2019 Aug;7(8):1224-1229

University of Maryland School of Medicine, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-19-0148DOI Listing
August 2019

Long-term remissions after stopping pembrolizumab for relapsed or refractory multiple myeloma.

Blood Adv 2019 Jun;3(11):1658-1660

Memorial Sloan Kettering Cancer Center and Weill-Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2019000191DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560349PMC
June 2019

Clinical Development of PD-1 Blockade in Hematologic Malignancies.

Cancer J 2018 Jan/Feb;24(1):31-35

From the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000297DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785103PMC
March 2019

Significant Nationwide Variability in the Costs and Hospital Mortality Rates of Autologous Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Nationwide Inpatient Sample Database.

Biol Blood Marrow Transplant 2019 01 6;25(1):41-46. Epub 2018 Sep 6.

Department of Medicine, Weill Cornell Medical College, New York, New York; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791183053
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2018.08.030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6661526PMC
January 2019

Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance.

Biol Blood Marrow Transplant 2018 04 27;24(4):871-876. Epub 2017 Dec 27.

Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2017.12.795DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6673673PMC
April 2018

Immunotherapy of Lymphoma and Myeloma: Facts and Hopes.

Clin Cancer Res 2018 03 12;24(5):1002-1010. Epub 2017 Sep 12.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-0539DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844779PMC
March 2018

Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance.

Leuk Lymphoma 2017 12 9;58(12):2962-2965. Epub 2017 May 9.

a Myeloma Service, Division of Hematologic Oncology, Department of Medicine , Memorial Sloan-Kettering Cancer Center , New York , NY , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1312382DOI Listing
December 2017

Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation.

Leuk Lymphoma 2017 08 12;58(8):1823-1831. Epub 2017 Jan 12.

b Department of Medicine, Adult Bone Marrow Transplant Service , Memorial Sloan Kettering Cancer Center, NY Presbyterian Hospital - Weill Cornell Medical College , New York , NY , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2016.1260126DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554510PMC
August 2017

A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.

Blood 2017 06 8;129(25):3294-3303. Epub 2017 May 8.

Section of Bone Marrow Transplantation & Leukemia, Division of Oncology, Department of Medicine, Washington University, St. Louis, MO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-09-740787DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482100PMC
June 2017

Immune checkpoint blockade for hematologic malignancies: a review.

Stem Cell Investig 2017 19;4:32. Epub 2017 Apr 19.

Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/sci.2017.03.04DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5420526PMC
April 2017

Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

J Clin Oncol 2017 Mar 30;35(7):709-717. Epub 2016 Sep 30.

Jarushka Naidoo, Kaitlin M. Woo, Tunc Iyriboz, Darragh Halpenny, Jane Cunningham, Jamie E. Chaft, Neil H. Segal, Margaret K. Callahan, Alexander M. Lesokhin, Jonathan Rosenberg, Martin H. Voss, Charles M. Rudin, Hira Rizvi, Xue Hou, Katherine Rodriguez, Melanie Albano, Ruth-Ann Gordon, Charles Leduc, Natasha Rekhtman, Bianca Harris, Jedd D. Wolchok, Michael A. Postow, and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center; Jamie E. Chaft, Neil H. Segal, Margaret K. Callahan, Alexander M. Lesokhin, Jonathan Rosenberg, Martin H. Voss, Charles M. Rudin, Jedd D. Wolchok, Michael A. Postow, and Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Jarushka Naidoo, Sidney Kimmel Cancer Center at Johns Hopkins University, Baltimore, MD; Xuan Wang, Peking University Cancer Hospital and Institute, Beijing; Xue Hou, Sun Yat-sen University Cancer Center, Guangdong Province, People's Republic of China; Xuan Wang, Matteo S. Carlino, Benjamin Y. Kong, and Georgina V. Long, The University of Sydney; Alexander M. Menzies and Alexander D. Guminski, Royal North Shore and Mater Hospital; and Matteo S. Carlino and Benjamin Y. Kong, Westmead and Blacktown Hospitals, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.2005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559901PMC
March 2017

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.

J Clin Oncol 2016 08 6;34(23):2698-704. Epub 2016 Jun 6.

Alexander M. Lesokhin and Deepika Cattry, Memorial Sloan Kettering Cancer Center; Alexander M. Lesokhin, Weill Cornell Medical College, New York, NY; Stephen M. Ansell, Mayo Clinic, Rochester, MN; Philippe Armand, Bjoern Chapuy, Gordon J. Freeman, Scott J. Rodig, and Margaret A. Shipp, Dana-Farber Cancer Institute; David Avigan, Beth Israel Deaconess Medical Center; Azra H. Ligon and Scott J. Rodig, Brigham and Women's Hospital, Boston, MA; Emma C. Scott, Oregon Health & Science University Knight Cancer Institute, Portland, OR; Ahmad Halwani, University of Utah Huntsman Cancer Institute, Salt Lake City, UT; Martin Gutierrez, Hackensack University Medical Center, Hackensack; Lili Zhu, Joseph F. Grosso, and M. Brigid Bradley Garelik, Bristol-Myers Squibb, Princeton, NJ; Michael M. Millenson, Fox Chase Cancer Center; Adam D. Cohen and Stephen J. Schuster, University of Pennsylvania, Philadelphia, PA; Daniel Lebovic, University of Michigan, Ann Arbor, MI; Madhav Dhodapkar, Yale Cancer Center, New Haven, CT; Ivan Borrello, Johns Hopkins University School of Medicine, Baltimore, MD; and John Timmerman, University of California, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.9789DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019749PMC
August 2016

Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1.

Cancer Immunol Res 2016 05 29;4(5):383-9. Epub 2016 Feb 29.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Weill Cornell Medical College, New York, New York. Department of Dermatology, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-15-0123DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241697PMC
May 2016

Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma.

Blood 2016 05 28;127(19):2355-6. Epub 2016 Mar 28.

Department of Medicine, Weill Medical College of Cornell University, New York, NY; Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-01-694786DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5003505PMC
May 2016

Transjugular Liver Biopsy in a Multiple Myeloma Patient with Hepatomegaly, Portal Hypertension and "Miliary" Liver Lesions: A Case Report.

J Gastrointest Dig Syst 2016 Feb 10;6(1). Epub 2016 Feb 10.

Radiology Department, Interventional Radiology Service, Memorial Sloan Kettering Cancer Center, York Avenue, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4172/2161-069X.1000390DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538783PMC
February 2016

T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy.

Cancer Immunol Res 2016 Jan 13;4(1):61-71. Epub 2015 Oct 13.

Laboratory of Cellular Immunobiology, Sloan Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York. Adult Bone Marrow Transplant Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. The Rockefeller University, New York, New York. Weill Cornell Medical College, New York, New York. Immunology Program, Sloan Kettering Institute for Cancer Research, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-15-0055DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4703436PMC
January 2016

Minimal residual disease in multiple myeloma: bringing the bench to the bedside.

Nat Rev Clin Oncol 2015 May 27;12(5):286-95. Epub 2015 Jan 27.

Myeloma Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2014.239DOI Listing
May 2015

On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation.

Sci Transl Med 2015 Mar;7(280):280sr1

Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Weill Cornell Medical College, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.3010274DOI Listing
March 2015

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

N Engl J Med 2015 Jan 6;372(4):311-9. Epub 2014 Dec 6.

From the Mayo Clinic, Rochester, MN (S.M.A.); Memorial Sloan Kettering Cancer Center (A.M.L., D.C.) and Weill Cornell Medical College (A.M.L.) - both in New York; Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, Baltimore (I.B.); University of Utah Huntsman Cancer Institute, Salt Lake City (A.H.); Oregon Health and Science University and the Knight Cancer Institute, Portland (E.C.S.); John Theurer Cancer Center, Hackensack University Medical Center, Hackensack (M.G.), and Bristol-Myers Squibb, Lawrenceville (L.Z., J.F.G., S.Y.K.) - both in New Jersey; Abramson Cancer Center, University of Pennsylvania (S.J.S.), and Fox Chase Cancer Center (M.M.M.) - both in Philadelphia; Dana-Farber Cancer Institute (G.J.F., B.C., M.A.S., P.A.) Brigham and Women's Hospital (S.J.R., A.H.L.), and Harvard Medical School (G.J.F., B.C., M.A.S., P.A., S.J.R., A.H.L.) - all in Boston; and Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles (J.M.T.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1411087DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4348009PMC
January 2015

Harnessing the immune system for cancer therapy.

Curr Opin Oncol 2014 Nov;26(6):600-7

aDepartment of Medicine, Memorial Sloan-Kettering Cancer Center bDivision of Gynecologic Medical Oncology, Memorial Sloan-Kettering Cancer Center cDepartment of Medicine, Weill Cornell Medical College dDivision of Myeloma, Memorial Sloan-Kettering Cancer Center, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000128DOI Listing
November 2014

Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes.

Cancer Immunol Res 2014 Aug 20;2(8):812-21. Epub 2014 May 20.

Memorial Sloan-Kettering Cancer Center; Weill-Cornell Medical and Graduate Schools; and Ludwig Collaborative and Swim Across America Lab, New York, New York

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-14-0013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4125466PMC
August 2014

Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanoma.

Methods Mol Biol 2014 ;1102:83-95

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-62703-727-3_6DOI Listing
June 2014

Myeloid-derived suppressor sells and the efficacy of CD8 T-cell immunotherapy.

Oncoimmunology 2013 Feb;2(2):e22764

Memorial Sloan-Kettering Cancer Center; New York, NY USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/onci.22764DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601158PMC
February 2013

Hiding the road signs that lead to tumor immunity.

J Exp Med 2011 Sep;208(10):1937-40

Swim Across America Laboratory, Immunology Program, Sloan-Kettering Institute for Cancer Research, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1084/jem.20111856DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3182053PMC
September 2011

Inhibition of chemokine expression by adenovirus early region three (E3) genes.

J Virol 2002 Aug;76(16):8236-43

Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York 10461, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC155150PMC
http://dx.doi.org/10.1128/jvi.76.16.8236-8243.2002DOI Listing
August 2002